Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human... Read more »
The latest startup to emerge from Flagship Pioneering aims to change drug discovery by starting the process with a clear understanding of cell behavior.
Cellarity—like many other startups looking to revamp... Read more »
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other kinds of disease.
Scripps’s early-stage... Read more »
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions.
Now French biopharma Sanofi has struck... Read more »
The name of the experimental drug was heard so frequently in hotel hallways at the conference that it sounded like an incantation: aducanumab, aducanumab, aducanumab.
Regardless of the eventual FDA verdict... Read more »
Acadia Pharmaceuticals revealed late-stage clinical data this week that could support bringing its drug for psychosis to a broader group of patients.
The Acadia (NASDAQ: ACAD) drug pimavanserin (Nuplazid) is... Read more »
It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to... Read more »
Biogen revealed detailed results from its Alzheimer’s trial to a jam-packed room of eager conference attendees this week—and while some described it as a major advance in the field, others were... Read more »
It’s the “era of neuroscience”; an industry “turning point”; and “an amazing time”—superlatives were flowing freely as the 12th annual Clinical Trials on Alzheimer’s Disease congress (CTAD) kicked off in rainy... Read more »
Scientists gathered this week in San Diego at the annual Clinical Trials on Alzheimer’s Disease Congress are focused on ways to treat the neurodegenerative disease, a task that continues to vex... Read more »
Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together.
San Francisco-based... Read more »
Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases.
It’s an all-cash deal worth $3 billion,... Read more »
Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the... Read more »
La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study.... Read more »
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML.
Those tools—artificial intelligence and machine learning, respectively—have been around for decades,... Read more »
A cancer tumor is a veritable patchwork of cells with a variety of genetic fingerprints.
Immunitas Therapeutics is using single-cell genomics—an approach that studies the genetic activity of individual cells—to peer... Read more »
A drug candidate once shelved by Takeda Pharmaceutical (NYSE: TAK) has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients with advanced... Read more »
About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases.
Now, with the completion of a clinical trial... Read more »
Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.
It’s still unclear whether the cases... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of... Read more »